AU5547000A - Novel treatment - Google Patents

Novel treatment

Info

Publication number
AU5547000A
AU5547000A AU55470/00A AU5547000A AU5547000A AU 5547000 A AU5547000 A AU 5547000A AU 55470/00 A AU55470/00 A AU 55470/00A AU 5547000 A AU5547000 A AU 5547000A AU 5547000 A AU5547000 A AU 5547000A
Authority
AU
Australia
Prior art keywords
novel treatment
novel
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55470/00A
Inventor
Ameet Nathwani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU5547000A publication Critical patent/AU5547000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
AU55470/00A 1999-06-14 2000-06-14 Novel treatment Abandoned AU5547000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9913782 1999-06-14
GBGB9913782.0A GB9913782D0 (en) 1999-06-14 1999-06-14 Novel compounds
PCT/GB2000/002330 WO2000076488A2 (en) 1999-06-14 2000-06-14 Use of a ppar agonist for treating type 1 diabetes

Publications (1)

Publication Number Publication Date
AU5547000A true AU5547000A (en) 2001-01-02

Family

ID=10855294

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55470/00A Abandoned AU5547000A (en) 1999-06-14 2000-06-14 Novel treatment

Country Status (3)

Country Link
AU (1) AU5547000A (en)
GB (1) GB9913782D0 (en)
WO (1) WO2000076488A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007603A (en) * 2000-03-09 2003-02-24 Aventis Pharma Gmbh Therapeutic uses of ppar mediators.
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
CA2913737A1 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
AU3091197A (en) * 1996-05-16 1997-12-05 Boehringer Mannheim Gmbh New process for preparing troglitazone
EP0953355A4 (en) * 1996-05-31 2002-02-27 Sankyo Co Remedy for autoimmune diseases
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
GB9913782D0 (en) 1999-08-11
WO2000076488A3 (en) 2001-05-10
WO2000076488A2 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
AU1173201A (en) Skin-gripper
AU3092999A (en) Digital-timeshare-exchange
AU2001271434A1 (en) Novel skateboard-bicycle combination
AU5089400A (en) Arthritis treatment
AU4431000A (en) Novel use
GB9925136D0 (en) Novel treatment
AU5967600A (en) Candystraw
PL349347A1 (en) Novel treatment
AU4115400A (en) Short-circuiter
AU6335000A (en) Depthimeter
AU5547000A (en) Novel treatment
AU2804600A (en) Arylaminoalkylamides
AU2023701A (en) Sketcher
AU6440900A (en) Homogentisate-dioxygenase
AU4556800A (en) Novel treatment
AU2699800A (en) Organoceramics
AU4916900A (en) Benzofuranylsulfonates
AU6098300A (en) Follistatin-3
AU2359301A (en) Novel ss-defensins
AU7273000A (en) Novel processes
AU4561600A (en) Benzofuranylaminoalcohols
AU1038501A (en) Novel processes
AU4456800A (en) Human hac3
AU1901801A (en) Glucofuranoses
AU4435300A (en) Hula-hoop

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase